Evidence map›Paper›PMID 37347533›Full record

ArticleJMIR formative research2023

Cancer Resource and Information Support (CRIS) for Bladder Cancer Survivors and Their Caregivers: Development and Usability Testing Study.

Michael A Diefenbach, Allison Marziliano, Elizabeth J Siembida, Thomas Mistretta, Halie Pfister, Andrea Yacoub, Kelli Aibel, Priya Patel, Emmanuel Lapitan, Erin K Tagai and 2 more

Open access · goldAbstract read
In one paragraph

Article in JMIR formative research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Michael A Diefenbach *Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, United States.ORCID https://orcid.org/0000-0003-2821-1507
Allison Marziliano *Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, United States.ORCID https://orcid.org/0000-0002-4762-1416
Elizabeth J Siembida *Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, United States.ORCID https://orcid.org/0000-0003-1131-8359
Thomas Mistretta *Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, United States.ORCID https://orcid.org/0009-0006-3131-432X
Halie Pfister *Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, United States.ORCID https://orcid.org/0009-0001-4573-5671
Andrea Yacoub *Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, United States.ORCID https://orcid.org/0009-0001-0563-741X
Kelli Aibel *Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, United States.ORCID https://orcid.org/0000-0003-1834-4293
Priya Patel *Institute of Health System Science, Feinstein Institutes for Medical Research, Northwell Health, New York, NY, United States.ORCID https://orcid.org/0000-0001-8379-048X
Emmanuel Lapitan *Cancer Prevention and Control, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, United States.ORCID https://orcid.org/0000-0003-4986-8524
Erin K Tagai *Cancer Prevention and Control, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, United States.ORCID https://orcid.org/0000-0001-8218-3848
Marc Smaldone *Surgical Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, United States.ORCID https://orcid.org/0000-0003-4160-0005
Suzanne M Miller *Cancer Prevention and Control, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, United States.ORCID https://orcid.org/0000-0002-7296-9318
Northwell Health · USFox Chase Cancer Center · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8M
Recovery Support for Bladder CA Patients and Caregivers: A Multimodal ApproachR01CA224918 · NCI · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI DIEFENBACH, MICHAEL A, MILLER, SUZANNE M · 2018 to 2023
$3.5M
NCI NIH HHS P30 CA006927NCI NIH HHS R01 CA224918
6 · The paper itself

Abstract

backgroundBladder cancer survivors and their caregivers face profound practical (eg, use of stoma appliances and care for urinary diversion methods) and psychosocial (eg, depression and anxiety) challenges after surgical treatment with cystectomy.

objectiveTo improve the health-related quality of life and postsurgical outcomes of both bladder cancer survivors and their caregivers, the team, in collaboration with Sourcetop, Inc (software design) and Dappersmith (graphic design), developed the Cancer Resource and Information Support (CRIS) software. The purpose of this manuscript is to report on the development and usability testing of the CRIS software.

methodsThe development of the CRIS software was guided by the Obesity-Related Behavioral Intervention Trials (ORBIT) model for developing behavioral treatments for chronic diseases. The ORBIT model is unique in that it proposes a flexible and progressive process with prespecific clinically significant milestones for forward movement and returns to earlier stages for refinement, and it facilitates communication among diverse groups by using terminology from the drug development model. This paper focuses on 2 phases of the ORBIT model: phase IA: define and IB: refine. During phase IA, the study team developed solutions for the stated clinical problem-adjustment to life post cystectomy-by reviewing the literature and collecting feedback from clinicians, professional organizations, bladder cancer survivors, and their caregivers. During Phase IB, the study team focused on tailoring content in the CRIS software to the user as well as usability testing with 7 participants.

resultsThe finished product is CRIS, a web-based software for survivors of bladder cancer and their caregivers to serve as a health management and lifestyle resource after surgery. Overarching themes from phase IA (participant feedback) included how to use new medical equipment, tips and tricks for easier living with new medical equipment, questions about health maintenance, and questions about lifestyle modifications. To accommodate our target population, we also incorporated recommendations from the Americans with Disabilities Act for website design, such as large text size, large paragraph spacing, highly contrasting text and background colors, use of headings and labels to describe the purpose of the content, portrait orientation without the need for horizontal scrolling, multiple ways to access a web page within a set of pages, ability to navigate web pages in sequential order, and in-text links that are descriptive. Usability participants evaluated CRIS very positively, indicating that it was easy to use, the functions were well-integrated, and if available, they would use CRIS frequently.

conclusionsCRIS, developed over the course of 18 months by integrating feedback from experts, literature reviews, and usability testing, is the first web-based software developed for bladder cancer survivors and their caregivers to help them adjust to life following cystectomy. The efficacy of CRIS in improving patients' and caregivers' quality of life is currently being evaluated in a randomized controlled trial.

Indexed as

behavioral intervention developmentmuscle invasive bladder cancerORBIT modelusability testingweb-based intervention

Identifiers

PMID37347533
PMCPMC10337367
OpenAlexW4381598814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.